Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Long-Term Investments (2019 - 2022)

Sutro Biopharma's Long-Term Investments history spans 4 years, with the latest figure at $20.7 million for Q1 2022.

  • For Q1 2022, Long-Term Investments fell 72.25% year-over-year to $20.7 million; the TTM value through Mar 2022 reached $20.7 million, down 72.25%, while the annual FY2021 figure was $68.8 million, N/A changed from the prior year.
  • Long-Term Investments for Q1 2022 was $20.7 million at Sutro Biopharma, down from $68.8 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $74.6 million in Q1 2021 and bottomed at $5.6 million in Q2 2020.
  • The 4-year median for Long-Term Investments is $20.7 million (2022), against an average of $34.3 million.
  • The largest annual shift saw Long-Term Investments soared 971.43% in 2021 before it tumbled 72.25% in 2022.
  • A 4-year view of Long-Term Investments shows it stood at $15.6 million in 2019, then plummeted by 64.12% to $5.6 million in 2020, then soared by 1128.12% to $68.8 million in 2021, then tumbled by 69.9% to $20.7 million in 2022.
  • Per Business Quant, the three most recent readings for STRO's Long-Term Investments are $20.7 million (Q1 2022), $68.8 million (Q4 2021), and $64.3 million (Q3 2021).